Investor Relations
Disclosures under Regulation 46 of the SEBI (LODR) Regulations, 2015.
Board of Directors
Board & Board Committees
| Name | Designation | Audit Committee | Risk Management Committee | Nomination & Remuneration Committee | Stakeholders Relationship Committee | CSR & ESG Committee | Treasury Management Committee |
|---|---|---|---|---|---|---|---|
| Mr. Aluri Srinivasa Rao | Independent Director | 
|
|
|
|
- | - |
| Dr. Anil Dhawan | Independent Director |
|
- |
|
|
|
- |
| Mr. Santanu Mukherjee | Independent Director |
|
|
|
- |
|
|
| Ms. Sundari R. Pisupati | Independent Director |
|
- |
|
|
|
- |
| Dr. Ramesh Kancharla | Chairman & Managing Director | - |
|
- |
|
|
|
| Dr. Dinesh Kumar Chirla | Whole-Time Director | - | - | - | - |
|
- |
| Dr. Adarsh Kancharla | Non-Executive Director | - | |
- | - |
| - |
| Mr. Vikas Maheshwari | Group Chief Financial Officer (KMP) | - |
|
- | - | - |
|
| Mr. Sanjeev Sukumaran | Group Chief Operating Officer (KMP) | - |
|
- | - | - | - |
Chairperson
Member
Policies & Programs
- Policy on determination of materiality for disclosure of events or information
- Familiarisation Programme for Independent Directors for FY 2022-23
- CSR Projects approved by the Board for FY 2022-23
- Archival Policy
- Dividend Distribution Policy
- Code of conduct for Directors and Senior Management
- Materiality Policy for identification of Material Creditors and for Litigation
- Policy for determining Material Group Companies
- Policy for determining Material Subsidiary
- Policy on materiality and dealing with the Related Party Transactions
- Terms and Conditions of appointment of Independent Directors
- Familiarization Programme for Independent Directors
- CSR Policy
- Policy on Board Diversity
- Nomination and Remuneration Policy
- Code of Practices and Procedures for Fair Disclosure of UPSI
- Whistle Blower Policy
- CSR Projects approved by the Board for FY 2021-22
- Business Responsibility Policy
- Familiarisation Programme for Independent Directors for FY 2021-22
Quarterly Results
Results for the Quarter & Year Ended March 31, 2024
Results for Quarter & Nine Months Ended December 31, 2023
Results for Quarter & Half Year Ended September 30, 2023
- Press Release Q2 & H1 FY2024
- Earnings Presentation Q2 & H1 FY2024
- UnAudited Financial Results – Q2 & H1 FY2024
- Analyst Concall Transcript Q2 & H1 FY24
Earnings call for Q2 & H1 FY 2024
Results for Quarter Ended June 30, 2023
- Press Release Q1 FY2024
- Earnings Presentation Q1 FY2024
- UnAudited Financial Results – Q1 FY2024
- Analyst Concall Transcript Q1 FY24
Earnings Call Audio Recording – Q1 FY 2024
Results for Quarter & Year Ended March 31, 2023
- Press Release Q4 FY2023
- Earnings Presentation Q4 FY2023
- Audited Financial Results – Q4 FY2023
- Analyst Concall Transcript Q4 & FY 23
Earnings Call Audio Recording – Q4 & FY 23
Results for Quarter & Nine Months Ended December 31, 2022
- Press Release Q3 & 9M FY2023
- Earnings Presentation Q3 & 9M FY2023
- UnAudited Financial Results – Q3 & 9M FY2023
- Analyst Concall Transcript Q3 & 9M FY2023
Earnings Call Audio Recording – Q3 & 9M FY2023
Results for Quarter & Half Year Ended September 30, 2022.
- Press Release Q2 & H1 FY2023.
- Earnings Presentation Q2 & H1 FY2023
- UnAudited Financial Results – Q2 & H1 FY2023
- Analyst Concall Transcript Q2 & H1 FY2023
Earnings Call Audio Recording – Q2 FY23
Results for Quarter Ended June 30, 2022
- Press Release Q1 FY2023
- Earnings Presentation Q1 FY2023
- UnAudited Financial Results Q1 FY2023
- Analyst Concall Transcript Q1 FY2023
Audio Recording Conference Call - Q1 FY23
Results for Quarter & Year Ended March 31, 2022
- Press Relase Q4 FY2022
- Earnings Presentation Q4 FY2022
- Audited Financial Results Q4 FY2022
- Analyst Webcast Transcript Q4 FY2022
Earnings Call Video Recording - Q4FY22
Subsidiary Financials
2022-23
- Rainbow Children's Hospital Private Limited RCHPL Financials 2022-23
- Rainbow Speciality Hospitals Private Limited RSHPL Financial 2022-23
- Rainbow Women & Children's Hospital Private Limited RWCHPL Financials 2022-23
- Rosewalk Healthcare Private Limited RHPL Financials 2022-23
- Rainbow Fertility Private Limited RFPL Financials 2022-23
- Rainbow C R O Private Limited RCROPL Financials 2022-23
2021-22
- Rainbow Children’s Hospital Private Limited RCHPL Financials 2021-22
- Rainbow Speciality Hospitals Private Limited RSHPL Financial 2021-22
- Rainbow Women & Children’s Hospital Private Limited RWCHPL Financials 2021-22
- Rosewalk Healthcare Private Limited RHPL Financials 2021-22
- Rainbow Fertility Private Limited RFPL Financials 2021-22
- Rainbow C R O Private Limited RCROPL Financials 2021-22
Stock Exchange Disclosures
Annual Secretarial Compliance Report
Certificate for Dematerialisation under Regulation 74(5) of SEBI Depository Participants Regulations
- Certificate under Regulation 74(5) - March 31, 2024
- Certificate under Regulation 74(5) - December 31, 2023
- Certificate under Regulation 74(5)- September 30, 2023
- Certificate under Regulation 74(5)- June 30, 2023
- Certificate under Regulation 74(5)- March 31, 2023
- Certificate under Regulation 74(5)- December 31, 2022
- Certificate under Regulation 74(5)- September 30, 2022
- Certificate under Regulation 74(5) - June 30, 2022
Closure of Trading Window
- Closure of Trading window – March 31, 2024
- Closure of Trading Window – December 31, 2023
- Closure of Trading Window – September 30, 2023
- Closure of Trading Window - June 30, 2023
- Closure of Trading Window- March 31, 2023
- Closure of Trading Window- December 31, 2022
- Closure of Trading Window– September 30, 2022
- Closure of Trading Window - June 30, 2022
- Closure of Trading Window - May 11, 2022
Compliance Certificate for Share Transfer Facility Under Regulation 7(3) of SEBI Listing Regulations
Compliance Certificate of Transfer/Sub division request(s) under Regulation 40(9) of SEBI Listing Regulations
Disclosure of Related Party Transactions under Regulation 23(9) of SEBI Listing Regulations
Disclosure under Regulation 30 of SEBI Listing Regulations and Miscellaneous Disclosures
- Outcome of Board Meeting – May 19, 2024
- Addition of 50 bed additional block - Hydernagar, Hyderabad, Telangana
- Commencement of a new 80 bed spoke hospital at Anna Nagar, Chennai, Tamil Nadu
- Commencement of a new 90 bed spoke hospital at Sarjapur, Bengaluru, Karnataka
- Outcome of Board Meeting – Appointment of Non - Executive Director – January 24, 2024
- Outcome of Board Meeting – January 24, 2024
- Commencement of a new 60 bed spoke hospital at Himayat Nagar, Hyderabad, Telangana
- Credit Rating Intimation– December 6, 2023
- Outcome of Board Meeting – Appointment of Independent Director - October 30, 2023
- Outcome of Board Meeting – October 30, 2023
- Stock Units granted – August 7, 2023
- Outcome of Board Meeting – August 7, 2023
- Update on purchase of land parcels located in Sector 44 & Sector 56 of Gurugram, Haryana
- Summary of Proceedings of 25th Annual General Meeting of the Company
- Outcome of Board Meeting – May 31, 2023
- Disclosure under Regulation 30(5)
- Purchase of Land Parcels - May 14, 2023
- Outcome of Board Meeting - May 14, 2023
- Outcome of Board Meeting - Appointment of Auditors - May 14, 2023
- Stock Units granted – May 14, 2023
- Intimation – Credit Rating – April 26, 2023
- Outcome of Board Meeting - April 15, 2023
- Outcome of Board Meeting - March 18, 2023
- Commencement of New Hospital Financial District
- Outcome of Board Meeting – February 9, 2023
- Outcome of Board Meeting – November 3, 2022
- Summary of Proceedings of 24th Annual General Meeting of the Company
- Commencement of new Hospital OMR Chennai Tamil Nadu
- Press Release with regard to opening of new Hospital at OMR Chennai Tamil Nadu
- Outcome of Board Meeting - August 08, 2022
- Outcome of Board Meeting - May 27, 2022
- Disclosure under Regulation 30(5)
- Resignation of Group Chief Operating Officer
- Information as per SEBI (SBEB) Regulations- FY 22
Initial Disclosure by Large Corporate
Monitoring Agency Report
- Monitoring Agency Report – March 31, 2024
- Monitoring Agency Report – December 31, 2023
- Monitoring Agency Report – September 30, 2023
- Monitoring Agency Report – June 30, 2023
- Monitoring Agency Report – March 31, 2023
- Monitoring Agency Report – December 31, 2022
- Monitoring Agency Report – September 30, 2022
- Monitoring Agency Report- June 30, 2022
Notice of Board Meeting
- Notice of Board Meeting – May 19, 2024
- Notice of Board Meeting - January 24, 2024
- Notice of Board Meeting- October 30, 2023
- Notice of Board Meeting- August 7, 2023
- Notice of Board Meeting- May 14, 2023
- Notice of Board Meeting- Feb 9, 2023
- Notice of Board Meeting- Nov 3, 2022
- Notice of Board Meeting - Aug 08, 2022
- Notice of Board Meeting - May 27, 2022
Reconciliation of Share Capital Audit Report
- Reconciliation of Share Capital Audit Report - March 31, 2024
- Reconciliation of Share Capital Audit Report - December 31, 2023
- Reconciliation of Share Capital Audit Report- September 30, 2023
- Reconciliation of Share Capital Audit Report- June 30, 2023
- Reconciliation of Share Capital Audit Report – March 31, 2023
- Reconciliation of Share Capital Audit Report- December 31, 2022
- Reconciliation of Share Capital Audit Report- September 30, 2022
- Reconciliation of Share Capital Audit Report - June 30, 2022
Report on Corporate Governance
- Corporate Governance Report – March 31, 2024
- Corporate Governance Report - December 31, 2023
- Corporate Governance Report- September 30, 2023
- Corporate Governance Report- June 30, 2023
- Corporate Governance Report - March 31, 2023
- Corporate Governance Report- December 31, 2022
- Corporate Governance Report – September 30, 2022
- Corporate Governance Report- June 30, 2022
Schedule of Analyst / Institutional Investor Meeting
- Q4 FY24 Concall Invite
- Intimation of Analyst/Institutional Investor Meet – February 29, 2024 & March 5, 2024
- Intimation of Analyst/Institutional Investor Meet - February 15 & 19 2024
- Q3 & 9M FY24 Concall Invite
- Intimation of Analyst/Institutional Investor Meet - November 21, 2023
- Q2 & H1 FY 24 Concall Invite
- Intimation of Analysts Institutional Investors Meet –September 25 & 26, 2023
- Intimation of Analysts Institutional Investors Meet – August 23, 2023
- Q1 FY 24 Concall Invite
- Intimation of Analysts Institutional Investors Meet - June 19, 2023
- Intimation of Analysts Institutional Investors Meet - June 8 & 9, 2023
- Q4 FY 23 Concall Invite
- Intimation of Analysts Institutional Investors Meet - March 13 to 15, 2023
- Intimation of Analysts Institutional Investor Meet - March 3, 2023
- Intimation of Analysts Institutional Investors Meet - Feb 28 & Mar 2, 2023
- Q3 & 9M FY 23 Concall Invite
- Intimation of Analysts/Institutional Investors Meet- December 9, 2022
- Intimation of Analysts/Institutional Investors Meet- November 16 to 17, 2022
- Intimation of Analysts/Institutional Investors Meet- November 7, 2022
- Q2 & H1 FY 23 Concall Invite
- Intimation of Analysts and Investor Meet – September 28, 2022
- Intimation of Analysts and Investor Meet - September 20, 2022
- Intimation of Analysts and Investor Meet - September 7, 2022
- Intimitation of Analysts/Institutional Investors Meet - August 12, 2022
- Q4 FY 22 Concall Invite
- Q1 FY 23 Concall Invite
Shareholding Pattern
- Shareholding Pattern as on March 31, 2024
- Shareholding Pattern December 31, 2023
- Shareholding Pattern September 30, 2023
- Shareholding Pattern as on June 30, 2023
- Shareholding Pattern as on March 31, 2023
- Shareholding Pattern as on December 31, 2022
- Shareholding pattern as on September 30, 2022
- Shareholding pattern as on June 30, 2022
- Shareholding Pattern as on May 06, 2022
Statement of Deviations or Variations
- Statement of Deviations or Variations – March 31, 2024
- Statement of Deviations or Variations – December 31, 2023
- Statement of Deviations or Variations – September 30, 2023
- Statement of Deviations or Variations – June 30, 2023
- Statement of Deviations or Variations – March 31, 2023
- Statement of Deviations or Variations –December 31, 2022.
- Statement of Deviations or Variations – September 30, 2022
- Statement of Deviations or Variations - June 30, 2022.
Statement of Investor Grievances under Regulation 13(3) of SEBI Listing Regulations
- Certificate under Regulation 13(3) – March 31, 2024
- Certificate under Regulation 13(3) – December 31, 2023
- Certificate under Regulation 13(3) – September 30, 2023
- Certificate under Regulation 13(3) – June 30, 2023
- Certificate under Regulation 13(3) - March 31, 2023
- Certificate under Regulation 13(3)- December 31, 2022
- Certificate under Regulation 13(3)- September 30, 2022
- Certificate under Regulation 13(3) - June 30, 2022
Dividend
Dividend Communications
Credit Rating
Credit Rating
| Date of Credit Rating | Name of Credit Rating Provider | Rating Assigned | ICRA Credit Rating letter |
|---|---|---|---|
| December 6, 2023 | ICRA Limited |
Long Term Rating - [ICRA] AA (Stable)
{Upgraded from [ICRA] AA- (Positive)} | View |
Listing on Stock Exchanges
Listing on Stock Exchanges
The Ordinary Shares of the Company are listed on the following 2 Stock Exchanges in India:
| Name Of Stock Exchange | Address | Stock Codes / Symbols |
|---|---|---|
| BSE Limited | Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001. | 543524 |
| National Stock Exchange of India Limited | Exchange Plaza, Bandra-Kurla Complex, Bandra East, Mumbai 400 051 | RAINBOW |
Investor Contact
For Analysts & Institutional Investors
Mr. Vikas Maheshwari,Chief Financial Officer
Mr. Saurabh Bhandari,Group Business Analyst
- 8-2-19/1/A, Daulet Arcade, Road No. 11, Banjara Hills, Hyderabad – 500 034, Telangana
- +91 40 49692244
- investorrelations@rainbowhospitals.in
For Investor Grievances/Officer(s) for the IEPF Authority
Ashish Kapil, Nodal Officer, Company Secretary & Compliance Officer
- 8-2-19/1/A, Daulet Arcade, Road No. 11, Banjara Hills, Hyderabad – 500 034, Telangana
- +91 40 49692244
- companysecretary@rainbowhospitals.in
KFin Technologies Limited
M Murali Krishna
- Plot 31 and 32, Financial District Nanakramguda, Serilingampally Hyderabad, Rangareddi 500 032, Telangana, India
- +91 40 6716 2222
- +91 40 49692244
- einward.ris@kfintech.com
